Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 1999

View Archived Issues

Company Profile: Antisoma

Progress in ARDS/ALI studies of lisofylline reported

Bio-Technology announces two oncology collaborations

Alpha1-antitrypsin may be a future treatment for asthma

Select Therapeutics submits IND in Canada

Celsion's BPH treatment completes phase I

Dusa to meet with FDA advisory panel to review Levulan

GAR-936, a potent glycylcycline antibiotic with excellent activity against resistant bacteria

FR-172516: pharmacological characterization of dual Ca2+ channel and beta-adrenoceptor blocker

Company Profile: D-Pharm

Targeted Genetics: Q1 1999 highlights

Chugai and Dainippon Ink & Chemicals to codevelop new antiallergic agent

BioChem Pharma: Q1 1999 highlights

Isis Pharmaceuticals: Q1 1999 highlights

Novo Nordisk: Annual Report 1998

Glaxo Wellcome dicloses novel class of serine protease inhibitors

Inhibitors of ras-transformed cell growth under study at Yuhan

Vitamin D3 analogues useful for osteoporosis, cancer and secondary hyperparathyroidism

Idec describes preparation, pharmacology and use of humanized anti-gp39 MAbs

New Incyte invention provides RBTNH and related products, and use thereof

New phase I/II study evaluates G-3139 + docetaxel

Novel Na+/H+ exchange inhibitor effective against reperfusion injury in rat MI model

More on Rhone-Poulenc/Hoechst merger

Infliximab promotes healing of fistulas in patients with Crohn's disease

E.U. marketing approval granted for Cetrotide

Different transdermal methods of estradiol administration produce different results

ArQule compound selected as IND candidate by Roche

Low-dose aspirin enhances success of assisted reproduction

Mechanism of hypolipidemic effects and potential antiatherogenic effects of NTE-122

New treatment guidelines for HIV-infected adults, adolescents now posted

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...